Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer
Status:
Active, not recruiting
Trial end date:
2022-09-13
Target enrollment:
Participant gender:
Summary
There has been limited benefit with angiogenesis inhibitor drugs in molecularly unselected
patients in non-small cell lung cancer (NSCLC). The investigators propose that patients who
are molecularly selected for treatment with nintedanib based on the presence of mutations in
the following genes: VEGFR1-3, PDGFR-A, PDGFR-B, FGFR1-3, and TP53, will have clinically
meaningful benefit in terms of response rate (RR) and progression-free survival (PFS).
Furthermore the investigators plan to correlate outcomes with specific mutations and evaluate
mechanisms of resistance.